Corcept Therapeutics Incorporated

CORT: Is Corcept Therapeutics Incorporated Halal?

Corcept Therapeutics Incorporated

NASDAQHealthcareUS

$83.12

+0.25%

Market Cap: 8.9B

Compliance Status

Halal

Screened on Jul 14, 2026 · AAOIFI Standard 21

A

Very Good

80Score

Is Corcept Therapeutics Incorporated (CORT) halal? Halal. Based on AAOIFI screening, Corcept Therapeutics Incorporated passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 80/100 (Grade: A).

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

0.1% of 30.0% limit

What this means for you

You can own CORT

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purify 3.4% of your income from CORT

That is about $3.40 of every $100 you earn from it. Donate this share to charity.

Calculate my exact amount

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 14, 2026

Compliance History

Halal, unchanged since May 2026.

No status changes recorded since we began tracking.

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q1 2026Data source: EDGAR
Free · No credit card required

Track CORT and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Corcept Therapeutics Incorporated (CORT) halal to invest in?
Based on AAOIFI Standard 21 screening, Corcept Therapeutics Incorporated (CORT) is rated Halal with a compliance grade of A (Very Good). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).
Why did Corcept Therapeutics Incorporated get a A compliance rating?
Corcept Therapeutics Incorporated (CORT) received a grade of A (Very Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.1% (limit 30%); interest-bearing deposits of 3.7% (limit 30%); prohibited income of 3.45% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Corcept Therapeutics Incorporated's Shariah verdict?
Corcept Therapeutics Incorporated's verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Corcept Therapeutics Incorporated re-screened for Shariah compliance?
Corcept Therapeutics Incorporated (CORT) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 14, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.